Indeed, short-term imatinib treatment increased OPG/RANKL ratio and osteocalcin levels in serum of CML patients [53], while long-term (> 2 years) imatinib therapy promoted bone formation [54] and increased bone mineral density (cortical bone mineralization) [55]. Here, TNFRSF11B is linked to chronic myelogenous leukemia, BCR-ABL1 positive.